Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?

Key Points

• Combination therapy demonstrates potential effectiveness in treating unresectable hepatocellular carcinoma, indicating new hope for patients.
• Overall response rates are improved with durvalumab and bevacizumab in conjunction with transarterial chemoembolization techniques.
• Analysis incorporates clinical outcomes from various cases that underwent this innovative treatment strategy.
• Findings support exploring this combination as a possible standard for unresectable hepatocellular carcinoma care.